按技术类型、应用、治疗领域、最终用户、产品类型和模式分類的能量治疗方法市场—2025-2032年全球预测

预计到 2032 年，能量治疗方法市场将成长至 131.1 亿美元，复合年增长率为 7.61%。

关键市场统计数据
基准年 2024	72.8亿美元
预计年份：2025年	78.5亿美元
预测年份 2032	131.1亿美元
复合年增长率 (%)	7.61%

本书清晰而富有远见地介绍了技术创新、临床需求和监管演变如何重塑各专科领域对能量治疗方法的采用。

过去十年间，能量治疗方法已从小众手术工具发展成为多个临床专科的基础平台。设备工程、影像整合和手术流程的创新，拓展了利用聚焦能量进行组织诊断、修復、消融和再生等治疗方法的临床应用范围。因此，临床医生和医疗系统正在重新调整治疗流程，以抓住机会，缩短手术时间、减少住院时间，并将治疗转移到门诊进行。

技术融合、服务主导的商业化和供应链重组将如何从根本上改变能量治疗方法的交付和应用

医疗格局正经历一场变革性的转变，其驱动力来自三个相互关联的因素：技术融合、医疗服务体系重组、实证商业化。设备小型化、影像导引标靶和软体控制技术的进步，使得治疗更加精准且微创。这种融合降低了门诊实施的技术门槛，将以往需要在医院进行的治疗转移到了诊所和居家医疗环境中。

评估关税引发的成本压力对全球能源相关医疗设备供应链的更广泛影响（营运、采购和产品开发）。

政策变化和关税有可能在全球医疗设备供应链中造成重大摩擦，而近期关税措施的累积影响正在重塑采购、製造和定价格局。医疗设备零件和成品进口成本的上升正促使原始设备製造商 (OEM) 重新评估供应商合同，加快替代供应商的资质认证，并在许多情况下建立区域製造地，以降低跨境关税波动带来的风险。这些策略转变与对高品质零件和特殊材料的持续需求同时发生，使得快速更换供应商变得更加复杂。

基于深度细分的洞察，揭示技术类型、临床应用、治疗领域、最终用户、产品类型和模式的交汇点，从而塑造策略重点。

了解能量治疗方法中临床需求、投资和创新集中方向的关键在于掌握细分市场的趋势。从技术层面来看，该市场涵盖冷冻疗法、电刺激疗法、高强度聚焦超音波、雷射（包括二氧化碳雷射、二极体雷射、铒：YAG雷射和钕：YAG雷射）、磁场疗法、微波疗法、双极、单极和POLA射频疗法以及超音波。每项技术在资本密集度、耗材需求和临床证据要求方面均有所不同，其中雷射和射频平台由于其精准性和多样化的施用器生态系统，通常价格分布更高。

不同区域的法规结构、商业化路径和製造生态系统如何创造差异化的机会和实施需求

区域趋势将对能量治疗方法开发商的监管策略、商业化时间表和生产重点产生重大影响。在美洲，由医院、门诊中心和专科诊所组成的成熟生态系统，在完善的监管路径和对临床证据的高度重视的支持下，正推动着那些展现出明确治疗效果的技术的应用。采购行为倾向于选择能够简化采购流程并提供培训和服务支援的捆绑式解决方案，而区域生产能力仍集中在能够支援产品快速改进的成熟产业丛集周围。

对成熟企业、专业创新者和跨学科伙伴关係如何塑造竞争、差异化和商业化路径的实用评估

能量治疗方法领域的竞争格局呈现出多元化的特点，既有成熟的医疗设备公司，也有专业系统製造商，还有专注于特定临床应用或底层技术的敏捷型Start-Ups。现有企业凭藉其丰富的产品系列和成熟的分销网络，通常将设备与耗材和服务合约捆绑销售。同时，敏捷的新兴参与企业则透过特定的临床证据、低资本密集度或创新的临床工作流程脱颖而出。随着企业将疗效追踪和远端监测纳入其价值提案，设备製造商与软体/分析提供者之间的合作也日益普遍。

领导者可以采取的切实可行的策略重点和有效手段，以降低风险、加速推广并建立永续的商业性优势。

产业领导者应优先采取一系列策略行动，加速产品在短期内的普及，同时保障消费者的选择权。首先，企业应实现供应商网路多元化，并投资于模组化产品架构，以降低关税和供应链风险，同时保持针对不同监管市场的设计弹性。其次，从产品开发的早期阶段开始，透过务实的临床试验和基于註册的研究，收集临床证据，对于确保获得有利的报销和支持基本契约谈判至关重要。第三，企业应采用整合的商业模式，将设备销售与耗材计画和软体服务结合，以创造持续收入并提高客户维繫留存率。

一个稳健的混合方法研究框架，结合专家访谈、监管和临床证据审查以及情境分析，以得出可靠的策略见解。

本执行摘要的研究综合采用了一种多方法论，将定性研究结果与已发表的监管和临床证据进行三角验证。主要研究包括对临床医生、采购主管和高阶相关人员进行结构化访谈，以了解实际应用中的推广驱动因素、流程和采购标准。次要研究涵盖了同行评审的临床文献、监管文件、专利概况和临床试验註册信息，以验证技术性能检验并找出证据缺口。

这份简明扼要的策略要点总结强调了基于证据的商业化、模组化产品设计以及增强区域执行力，以实现持续的价值创造。

总之，能量治疗方法正处于一个转捩点。技术进步、医疗服务模式的转变以及不断变化的商业性需求相互交织，为改善患者疗效和创建新的经营模式创造了重大机会。在此环境下取得成功，取决于能否将严谨的临床证据与灵活的商业策略相结合，以满足不同的终端用户需求、适应区域监管环境并应对供应链的实际情况。能够提供兼具清晰的经济和临床价值，同时又能降低流程复杂性的整合解决方案的公司，将最有可能获得持续的市场认可。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 在老龄化社会中扩大家用光生物调节设备在慢性疼痛管理的应用
• 将人工智慧驱动的治疗计画整合到高强度聚焦超音波肿瘤治疗中
• 射频微针设备在微创美容紧肤疗程的应用​​日益广泛
• 开发用于治疗特定肌肉骨骼损伤的携带式低强度衝击波治疗平台
• 监管核准和报销政策的变化推动了非侵入式塑形解决方案的成长
• 一种用于协同皮肤治疗的雷射和射频联合平台的出现
• 用于非侵入性神经治疗的超音波导引神经调控装置的创新

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依技术类型分類的能量治疗方法市场

• 冷冻疗法
• 电刺激
• 高强度聚焦超音波
• 雷射
  • 二氧化碳雷射
  • 二极体雷射
  • 铒YAG雷射
  • Nd:YAG雷射
• 磁疗
• 微波疗法
• 高频
  • 双极
  • 单极
  • 多极
• 超音波

9. 按应用分類的能量治疗方法市场

• 美丽
  • 塑形
  • 除毛
  • 疤痕治疗
  • 皮肤修復
    • 皮肤紧緻
    • 分段式表面置换
    • 光子嫩肤
  • 去除纹身
  • 减少皱纹
• 心血管系统
  • 血管成形术
  • 心律不整治疗
  • 血管外科
• 肿瘤学
  • 乳癌
  • 肝癌
  • 摄护腺癌
• 眼科
  • 白内障治疗
  • 青光眼治疗
  • 视网膜治疗
• 疼痛管理
  • 腰痛
  • 关节疼痛
  • 肌肉骨骼疼痛
  • 神经病变疼痛
• 物理治疗
  • 肌肉刺激
  • 復原
  • 肿胀减轻
  • 创伤治疗
• 外科手术
  • 心血管外科
  • 眼科手术
  • 止血
  • 组织切除
  • 肿瘤切除

10. 按治疗领域分類的能量治疗方法市场

• 心臟病学
• 皮肤科
• 神经病学
• 肿瘤学
• 整形外科

第十一章：按最终用户分類的能量治疗方法市场

• 门诊手术中心
• 皮肤科诊所
• 居家医疗环境
• 医院
• 物理治疗中心

第十二章：按产品类型分類的能量治疗方法市场

• 配件和耗材
• 装置
• 服务和软体

13. 按模式分類的能量治疗方法市场

• 侵入性
• 微创
• 非侵入性

14. 各地区能量治疗方法市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十五章：按组别分類的能量治疗方法市场

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

16. 各国能量治疗方法市场概况

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十七章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • AbbVie Inc.
  • Hologic, Inc.
  • Lumenis Ltd.
  • Cutera, Inc.
  • InMode Ltd.
  • Sisram Medical Ltd.
  • Bausch Health Companies Inc.
  • Venus Concept Inc.
  • Candela Corporation
  • Strata Skin Sciences, Inc.

The Energy-Based Therapeutics Market is projected to grow by USD 13.11 billion at a CAGR of 7.61% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 7.28 billion
Estimated Year [2025]	USD 7.85 billion
Forecast Year [2032]	USD 13.11 billion
CAGR (%)	7.61%

A clear, forward-looking primer on how technological innovation, clinical demand, and regulatory evolution are reshaping energy-based therapeutic adoption across specialties

The past decade has seen energy-based therapeutics transition from niche procedural tools into foundational platforms across multiple clinical specialties. Innovations in device engineering, imaging integration, and procedure workflows have expanded the clinical footprint of therapies that use focused energy to diagnose, modulate, ablate, or regenerate tissue. As a result, clinicians and health systems are recalibrating treatment algorithms to take advantage of shorter procedure times, reduced hospitalization, and opportunities to shift care toward ambulatory and outpatient settings.

Regulatory pathways and reimbursement environments are evolving in parallel, shaping adoption curves and influencing design priorities for new product entrants. Manufacturers now face a dual imperative: demonstrating robust clinical evidence that substantiates safety and long-term outcomes while also articulating clear economic value propositions for payors and providers. Concurrently, patient expectations for less invasive, more precise, and cosmetically favorable interventions are accelerating demand across aesthetic and therapeutic indications. Taken together, these forces are reorienting investment, partnership, and commercialization strategies across the ecosystem of device developers, service providers, and clinical adopters.

How technological convergence, service-led commercialization, and supply chain realignment are driving a fundamental shift in energy-based therapeutics delivery and adoption

The landscape is undergoing transformative shifts driven by three intersecting vectors: technological convergence, care delivery reorganization, and evidence-based commercialization. Advances in device miniaturization, imaging-guided targeting, and software-enabled controls are enabling treatments that are simultaneously more precise and less invasive. This convergence has lowered technical barriers to adoption in outpatient and ambulatory settings, allowing procedures that once required hospital infrastructure to migrate into clinics and homecare environments.

Simultaneously, the commercialization model is shifting from a purely product-centric approach to integrated solutions that bundle equipment with consumables, digital services, and outcome-monitoring software. Value-based reimbursement models and growing scrutiny on total cost of care are pressuring stakeholders to demonstrate longitudinal patient benefits, not just procedural efficacy. As a result, companies that can pair clinical evidence with service-oriented delivery models and robust real-world data capture are positioned to gain preferential adoption. Finally, external pressures such as supply chain volatility and geopolitical shifts are accelerating near-shoring and supplier diversification strategies, prompting manufacturers to rethink component sourcing and lifecycle management.

Assessing the broad operational, procurement, and product development implications of tariff-driven cost pressures on global energy-based device supply chains

Policy changes and tariff implementations can create material friction across a global medical device supply chain, and the cumulative impact of recent tariff actions is reshaping procurement, manufacturing, and pricing dynamics. Increased import costs for device components and finished goods have prompted original equipment manufacturers to revisit supplier contracts, accelerate qualification of alternative vendors, and in many cases to explore regional manufacturing footprints that reduce exposure to cross-border tariff volatility. These strategic shifts are occurring alongside continued demand for high-quality components and specialized materials, which complicates rapid supplier substitution.

For hospitals, clinics, and ambulatory surgical centers, the direct effect is often higher capital outlay or incremental pricing pressure on consumables, which in turn influences purchasing prioritization and the relative attractiveness of bundled service agreements. Meanwhile, developers face an elevated cost base for R&D and prototyping when critical components become more expensive or less reliably available. Over time, tariff-driven cost pressures can influence product roadmaps by elevating the importance of modularity, component standardization, and software-driven feature differentiation that reduces reliance on high-cost hardware. To mitigate these impacts, strategic responses observed across the industry include diversified supplier networks, near-shore manufacturing investments, and contractual hedging strategies that align stocking policies with forecasted demand and regulatory timelines.

Deep segmentation-driven insights revealing where technology types, clinical applications, therapeutic areas, end users, product types, and modes intersect to shape strategic priorities

Segment-specific dynamics are central to understanding where clinical demand, investment, and innovation are concentrated across the energy-based therapeutics landscape. On the technology front, the market encompasses Cryotherapy, Electrical Stimulation, High Intensity Focused Ultrasound, Laser-including CO2 Laser, Diode Laser, Erbium YAG Laser, and Nd:YAG Laser-Magnetic Field Therapy, Microwave Therapy, Radio Frequency across Bipolar, Monopolar, and Multipolar configurations, and Ultrasound. Each technological family has distinct capital intensity, consumable requirements, and clinical evidence expectations, with lasers and radio frequency platforms often commanding premium pricing due to precision capabilities and diverse applicator ecosystems.

Application-driven segmentation reveals differentiated adoption curves and clinical priorities. Aesthetics applications such as Body Contouring, Hair Removal, Scar Treatment, Skin Rejuvenation-spanning Dermal Tightening, Fractional Resurfacing, and Photofacial-Tattoo Removal, and Wrinkle Reduction are driving rapid commercial uptake in clinic and ambulatory settings where patient demand and procedural revenue are high. Cardiovascular applications including Angioplasty, Arrhythmia Treatment, and Vascular Surgery require rigorous regulatory and clinical validation but offer substantial clinical impact. Oncology applications focused on Breast Cancer, Liver Cancer, and Prostate Cancer demand integration with imaging and multidisciplinary care pathways, while Ophthalmology applications from Cataract Treatment to Glaucoma Treatment and Retinal Therapies emphasize miniaturization and precision. Pain Management covering Back Pain, Joint Pain, Musculoskeletal Pain, and Neuropathic Pain and Physiotherapy fields such as Muscle Stimulation, Rehabilitation, Swelling Reduction, and Wound Healing often favor devices that balance efficacy with low procedural complexity. Surgical indications that include Cardiovascular Surgery, Eye Surgery, Hemostasis, Tissue Ablation, and Tumor Resection place a premium on device reliability and intraoperative ergonomics.

Therapeutic area distinctions-Cardiology, Dermatology, Neurology, Oncology, and Orthopedics-inform clinical trial design and commercial access strategies, while end-user diversity spanning Ambulatory Surgical Centers, Dermatology Clinics, Homecare Settings, Hospitals, and Physiotherapy Centers drives differentiated service and training requirements. Product-level segmentation into Accessories & Consumables, Equipment, and Services & Software underscores the evolving business models where recurring consumables and outcome-monitoring software can create sustained revenue streams. Mode of delivery-Invasive, Minimally Invasive, and Non Invasive-continues to shape regulatory classification, patient recovery expectations, and purchaser criteria. By synthesizing these segmentation layers, stakeholders can prioritize investments where clinical need, reimbursement potential, and operational feasibility converge, tailoring product roadmaps and commercial propositions to the nuances of each segment.

How distinct regulatory frameworks, commercialization pathways, and manufacturing ecosystems across major global regions create differentiated opportunities and execution demands

Regional dynamics significantly influence regulatory strategy, commercialization timelines, and manufacturing priorities for energy-based therapeutic developers. In the Americas, a mature ecosystem of hospitals, ambulatory centers, and specialist clinics is supported by a well-established regulatory pathway and a strong emphasis on clinical evidence, which facilitates adoption for technologies that demonstrate clear outcome improvements. Purchasing behavior tends to favor bundled solutions that simplify procurement and provide training and service support, and regional manufacturing capacity remains concentrated around established clusters that support rapid product iteration.

Across Europe, the Middle East & Africa, regulatory diversity creates both complexity and opportunity. European markets are influenced by harmonized regulatory frameworks and evolving medical device requirements that drive rigorous conformity and post-market surveillance expectations. In many Middle Eastern and African markets, adoption is uneven, with pockets of rapid modernization in urban centers and a growing appetite for devices suited to outpatient or clinic-based care. The Asia-Pacific region exhibits heterogeneity driven by strong manufacturing capabilities, rapidly expanding private healthcare networks, and a growing prevalence of aesthetic and elective procedures. Local R&D centers and contract manufacturers in the region accelerate cost-competitive production, while rising patient demand in urban centers creates sizable opportunities for scalable, lower-cost solutions. Each regional bloc therefore requires distinct go-to-market approaches, regulatory roadmaps, and partnership strategies to align with localized payer models, clinical practice patterns, and supply chain realities.

A pragmatic assessment of how established firms, focused innovators, and cross-disciplinary partnerships are shaping competition, differentiation, and commercialization paths

Competitive dynamics in energy-based therapeutics are characterized by a mix of established medical device firms, specialized system manufacturers, and agile start-ups that often focus on niche clinical applications or enabling technologies. Incumbents frequently leverage broad product portfolios and established distribution networks to bundle equipment with consumables and service contracts, while nimble entrants differentiate on targeted clinical evidence, lower capital intensity, or novel clinical workflows. Partnerships between device makers and software or analytics providers are increasingly prevalent as companies seek to embed outcome tracking and remote monitoring into their value propositions.

Intellectual property, regulatory approvals, and high-quality clinical data remain key barriers to market entry. Therefore, strategic activity often centers on acquiring complementary technologies, forging clinical collaborations, and investing in post-market studies that reinforce safety and long-term efficacy claims. Companies that effectively align product design with end-user operational needs-optimizing ergonomics for surgeons, workflow integration for clinics, and remote support capabilities for homecare-are able to accelerate adoption and create defensible positions. Finally, service-led models and consumable-driven revenue streams are becoming critical levers for sustaining commercial momentum once clinical acceptance is achieved.

Actionable strategic priorities and pragmatic execution levers that leaders can deploy to mitigate risk, accelerate adoption, and build durable commercial advantage

Industry leaders should prioritize a set of strategic actions that preserve optionality while accelerating near-term adoption. First, companies should diversify supplier networks and invest in modular product architectures to reduce tariff and supply chain exposure while preserving design flexibility for different regulatory markets. Second, embedding clinical evidence generation into early product development-through pragmatic trials and registry-based studies-will be essential to secure favorable reimbursement and to support value-based contracting discussions. Third, firms should adopt integrated commercial models that combine equipment sales with consumable programs and software-enabled services to create recurring revenue and improve customer retention.

Additionally, targeted regional strategies will be vital: prioritize high-value clinical indications and geographies with clear regulatory pathways and reimbursement readiness while deploying scalable rollouts in markets with strong outpatient and private clinic penetration. Leaders should also invest in digital ecosystems that enable remote monitoring, outcome measurement, and telehealth-enabled follow-up, thereby enhancing the overall patient experience and strengthening payer conversations. Finally, organizational capability-building-focused on cross-functional regulatory expertise, clinical affairs, and health economics-will accelerate navigation of complex approval pathways and support sustainable market access. By pursuing these coordinated actions, companies can reduce execution risk while maximizing the commercial impact of new product introductions.

A robust mixed-methods research framework combining expert interviews, regulatory and clinical evidence review, and scenario analysis to produce defensible strategic insights

The research synthesis underpinning this executive summary integrates a multi-method approach designed to triangulate qualitative insights with publicly available regulatory and clinical evidence. Primary research included structured interviews with clinicians, procurement leaders, and executive stakeholders to capture real-world adoption drivers, procedural workflows, and purchasing criteria. Secondary analysis encompassed peer-reviewed clinical literature, regulatory filings, patent landscapes, and clinical trial registries to validate technology performance claims and to map evidence gaps.

Data synthesis techniques included thematic analysis of expert interviews, comparative review of regulatory frameworks across major geographies, and scenario-based evaluation of supply chain and tariff impacts. Where direct data were limited, findings were corroborated through cross-validation with clinician advisory panels and simulation of commercial adoption pathways. Quality controls included source triangulation and independent review of clinical interpretations to ensure robustness. Limitations of the methodology are acknowledged, including variability in near-term policy changes and regional reimbursement heterogeneity, and recommendations emphasize adaptive strategies that remain robust across plausible regulatory and market scenarios.

A concise synthesis of strategic takeaways emphasizing evidence-led commercialization, modular product design, and resilient regional execution to capture lasting value

In conclusion, energy-based therapeutics stand at an inflection point where technological advancement, shifting care delivery models, and evolving commercial imperatives converge to create meaningful opportunities for improved patient outcomes and new business models. Success in this environment will hinge on the ability to couple rigorous clinical evidence with flexible commercial strategies that address diverse end-user needs, regional regulatory landscapes, and supply chain realities. Those who can deliver integrated solutions that reduce procedural complexity while demonstrating clear economic and clinical value will be best positioned to capture sustained adoption.

Looking ahead, manufacturers and investors should remain focused on modular product design, evidence-driven market entry, and service-oriented revenue models. Coordinated investments in regional manufacturing resilience, strategic partnerships, and digital health capabilities will mitigate external risks and amplify product differentiation. The path forward rewards strategic patience combined with decisive, evidence-backed market action.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Expansion of home-use photobiomodulation devices for chronic pain management in aging populations
• 5.2. Integration of AI-driven treatment planning in high-intensity focused ultrasound oncology therapies
• 5.3. Rising adoption of radiofrequency microneedling devices for minimally invasive aesthetic skin tightening
• 5.4. Development of portable low-intensity shockwave therapy platforms for targeted musculoskeletal injuries
• 5.5. Regulatory approval and reimbursement changes driving growth in noninvasive body contouring solutions
• 5.6. Emergence of combined laser and radiofrequency platforms for synergistic dermatological treatments
• 5.7. Innovation in ultrasound-guided neuromodulation devices for noninvasive neurological disorder interventions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Energy-Based Therapeutics Market, by Technology Type

• 8.1. Cryotherapy
• 8.2. Electrical Stimulation
• 8.3. High Intensity Focused Ultrasound
• 8.4. Laser
  • 8.4.1. CO2 Laser
  • 8.4.2. Diode Laser
  • 8.4.3. Erbium YAG Laser
  • 8.4.4. Nd:YAG Laser
• 8.5. Magnetic Field Therapy
• 8.6. Microwave Therapy
• 8.7. Radio Frequency
  • 8.7.1. Bipolar
  • 8.7.2. Monopolar
  • 8.7.3. Multipolar
• 8.8. Ultrasound

9. Energy-Based Therapeutics Market, by Application

• 9.1. Aesthetics
  • 9.1.1. Body Contouring
  • 9.1.2. Hair Removal
  • 9.1.3. Scar Treatment
  • 9.1.4. Skin Rejuvenation
    • 9.1.4.1. Dermal Tightening
    • 9.1.4.2. Fractional Resurfacing
    • 9.1.4.3. Photofacial
  • 9.1.5. Tattoo Removal
  • 9.1.6. Wrinkle Reduction
• 9.2. Cardiovascular
  • 9.2.1. Angioplasty
  • 9.2.2. Arrhythmia Treatment
  • 9.2.3. Vascular Surgery
• 9.3. Oncology
  • 9.3.1. Breast Cancer
  • 9.3.2. Liver Cancer
  • 9.3.3. Prostate Cancer
• 9.4. Ophthalmology
  • 9.4.1. Cataract Treatment
  • 9.4.2. Glaucoma Treatment
  • 9.4.3. Retinal Therapies
• 9.5. Pain Management
  • 9.5.1. Back Pain
  • 9.5.2. Joint Pain
  • 9.5.3. Musculoskeletal Pain
  • 9.5.4. Neuropathic Pain
• 9.6. Physiotherapy
  • 9.6.1. Muscle Stimulation
  • 9.6.2. Rehabilitation
  • 9.6.3. Swelling Reduction
  • 9.6.4. Wound Healing
• 9.7. Surgical
  • 9.7.1. Cardiovascular Surgery
  • 9.7.2. Eye Surgery
  • 9.7.3. Hemostasis
  • 9.7.4. Tissue Ablation
  • 9.7.5. Tumor Resection

10. Energy-Based Therapeutics Market, by Therapeutic Area

• 10.1. Cardiology
• 10.2. Dermatology
• 10.3. Neurology
• 10.4. Oncology
• 10.5. Orthopedics

11. Energy-Based Therapeutics Market, by End User

• 11.1. Ambulatory Surgical Centers
• 11.2. Dermatology Clinics
• 11.3. Homecare Settings
• 11.4. Hospitals
• 11.5. Physiotherapy Centers

12. Energy-Based Therapeutics Market, by Product Type

• 12.1. Accessories & Consumables
• 12.2. Equipment
• 12.3. Services & Software

13. Energy-Based Therapeutics Market, by Mode

• 13.1. Invasive
• 13.2. Minimally Invasive
• 13.3. Non Invasive

14. Energy-Based Therapeutics Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Energy-Based Therapeutics Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Energy-Based Therapeutics Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. AbbVie Inc.
  • 17.3.2. Hologic, Inc.
  • 17.3.3. Lumenis Ltd.
  • 17.3.4. Cutera, Inc.
  • 17.3.5. InMode Ltd.
  • 17.3.6. Sisram Medical Ltd.
  • 17.3.7. Bausch Health Companies Inc.
  • 17.3.8. Venus Concept Inc.
  • 17.3.9. Candela Corporation
  • 17.3.10. Strata Skin Sciences, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MODE, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MODE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. AMERICAS ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. NORTH AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. LATIN AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. EUROPE ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. MIDDLE EAST ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. ASEAN ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. GCC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. EUROPEAN UNION ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. BRICS ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. G7 ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. NATO ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. ENERGY-BASED THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 32. ENERGY-BASED THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. ENERGY-BASED THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CRYOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CRYOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CRYOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CRYOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CRYOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CRYOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ELECTRICAL STIMULATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ELECTRICAL STIMULATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ELECTRICAL STIMULATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ELECTRICAL STIMULATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ELECTRICAL STIMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ELECTRICAL STIMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CO2 LASER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CO2 LASER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CO2 LASER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CO2 LASER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CO2 LASER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CO2 LASER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DIODE LASER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DIODE LASER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DIODE LASER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DIODE LASER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DIODE LASER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DIODE LASER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ERBIUM YAG LASER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ERBIUM YAG LASER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ERBIUM YAG LASER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ERBIUM YAG LASER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ERBIUM YAG LASER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ERBIUM YAG LASER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ND:YAG LASER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ND:YAG LASER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ND:YAG LASER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ND:YAG LASER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ND:YAG LASER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ND:YAG LASER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MAGNETIC FIELD THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MAGNETIC FIELD THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MAGNETIC FIELD THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MAGNETIC FIELD THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MAGNETIC FIELD THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MAGNETIC FIELD THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MICROWAVE THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MICROWAVE THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MICROWAVE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MICROWAVE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MICROWAVE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MICROWAVE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BIPOLAR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BIPOLAR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BIPOLAR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BIPOLAR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BIPOLAR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BIPOLAR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MONOPOLAR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MONOPOLAR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MONOPOLAR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MONOPOLAR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MONOPOLAR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MONOPOLAR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MULTIPOLAR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MULTIPOLAR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MULTIPOLAR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MULTIPOLAR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MULTIPOLAR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MULTIPOLAR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BODY CONTOURING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BODY CONTOURING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BODY CONTOURING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BODY CONTOURING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BODY CONTOURING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BODY CONTOURING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HAIR REMOVAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HAIR REMOVAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HAIR REMOVAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HAIR REMOVAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HAIR REMOVAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HAIR REMOVAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SCAR TREATMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SCAR TREATMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SCAR TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SCAR TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SCAR TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SCAR TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DERMAL TIGHTENING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DERMAL TIGHTENING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DERMAL TIGHTENING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DERMAL TIGHTENING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DERMAL TIGHTENING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DERMAL TIGHTENING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY FRACTIONAL RESURFACING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY FRACTIONAL RESURFACING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY FRACTIONAL RESURFACING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY FRACTIONAL RESURFACING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY FRACTIONAL RESURFACING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY FRACTIONAL RESURFACING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHOTOFACIAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHOTOFACIAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHOTOFACIAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHOTOFACIAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHOTOFACIAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHOTOFACIAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TATTOO REMOVAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TATTOO REMOVAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TATTOO REMOVAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TATTOO REMOVAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TATTOO REMOVAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TATTOO REMOVAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY WRINKLE REDUCTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY WRINKLE REDUCTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY WRINKLE REDUCTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY WRINKLE REDUCTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY WRINKLE REDUCTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY WRINKLE REDUCTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ANGIOPLASTY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ANGIOPLASTY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ANGIOPLASTY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ANGIOPLASTY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ANGIOPLASTY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ANGIOPLASTY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ARRHYTHMIA TREATMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ARRHYTHMIA TREATMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ARRHYTHMIA TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ARRHYTHMIA TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ARRHYTHMIA TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ARRHYTHMIA TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY VASCULAR SURGERY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY VASCULAR SURGERY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY VASCULAR SURGERY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY VASCULAR SURGERY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY VASCULAR SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY VASCULAR SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 217. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 218. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 219. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2024 (USD MILLION)
• TABLE 220. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 223. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 224. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 225. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 226. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 227. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CATARACT TREATMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 228. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CATARACT TREATMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 229. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CATARACT TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 230. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CATARACT TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 231. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CATARACT TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 232. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CATARACT TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 233. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY GLAUCOMA TREATMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 234. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY GLAUCOMA TREATMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 235. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY GLAUCOMA TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 236. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY GLAUCOMA TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 237. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY GLAUCOMA TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 238. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY GLAUCOMA TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 239. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RETINAL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 240. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RETINAL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 241. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RETINAL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 242. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RETINAL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 243. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RETINAL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 244. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RETINAL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 245. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
• TABLE 246. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
• TABLE 247. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 248. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 249. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 250. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 251. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 252. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 253. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BACK PAIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 254. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BACK PAIN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 255. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BACK PAIN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 256. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BACK PAIN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 257. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BACK PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 258. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BACK PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 259. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY JOINT PAIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 260. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY JOINT PAIN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 261. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY JOINT PAIN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 262. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY JOINT PAIN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 263. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY JOINT PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 264. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY JOINT PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 265. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MUSCULOSKELETAL PAIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 266. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MUSCULOSKELETAL PAIN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 267. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MUSCULOSKELETAL PAIN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 268. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MUSCULOSKELETAL PAIN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 269. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MUSCULOSKELETAL PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 270. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MUSCULOSKELETAL PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 271. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 272. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 273. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 274. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 275. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 276. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 277. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 278. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 279. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 280. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 281. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 282. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 283. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 284. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 285. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MUSCLE STIMULATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 286. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MUSCLE STIMULATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 287. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MUSCLE STIMULATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 288. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MUSCLE STIMULATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 289. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MUSCLE STIMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 290. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MUSCLE STIMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 291. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY REHABILITATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 292. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY REHABILITATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 293. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY REHABILITATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 294. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY REHABILITATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 295. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY REHABILITATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 296. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY REHABILITATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 297. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SWELLING REDUCTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 298. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SWELLING REDUCTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 299. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SWELLING REDUCTION, BY GROUP, 2018-2024 (USD MILLION)